# Regeneron Upgraded to Buy as Wall Street Underestimates Dupixent Growth

- URL: https://stocks.freetheai.org/news/regeneron-upgraded-to-buy-as-wall-street-underestimates-dupixent-growth-eac290
- Published: 2026-10-14T21:42:05Z
- Category: analyst_ratings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:REGN](https://stocks.freetheai.org/symbols/NASDAQ-REGN), [NASDAQ:SNY](https://stocks.freetheai.org/symbols/NASDAQ-SNY)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a rating upgrade to Buy from Neutral, accompanied by a new price target of $978. The updated valuation target implies roughly 30% upside potential from recent closing levels. Shares of the biotech firm rose 3.35% to $778.40 following the action.

The bullish call stems from Wall Street underestimating the long-term potential of blockbuster treatment Dupixent (dupilumab), which is co-developed alongside Sanofi SA (NASDAQ:SNY). Analysts project Dupixent revenue could hit $16 billion by 2035, significantly higher than the broader market consensus of $13 billion.

Key milestones lie ahead as Regeneron advances four next-generation Dupixent candidates designed to extend market exclusivity past 2031. Initial clinical trial data for the lead candidate is expected early next year, with Phase 3 testing targeted for the second half of 2027. Early-stage trials for the remaining three candidates are scheduled to begin in early 2027.

## Key points

- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was upgraded to Buy with a target price of $978.
- Analysts forecast 2035 Dupixent revenue at $16 billion, exceeding the $13 billion consensus estimate.
- Four next-generation Dupixent candidates are in development to extend product exclusivity.
- Data from the first candidate readout is expected early next year before entering Phase 3 in late 2027.

## Questions and answers

### Why was Regeneron Pharmaceuticals stock upgraded?

The stock was upgraded due to overlooked potential in its next-generation Dupixent pipeline and the likelihood of extending market exclusivity beyond 2031.

### What is the target price for Regeneron stock?

The target price was set at $978 per share, offering around 30% upside from recent closing prices.

### What are the timeline expectations for next-generation Dupixent?

The first candidate could release study data early next year and start Phase 3 trials in late 2027. Early-stage trials for three other candidates are planned for early 2027.